Bio Pharma Dive

MARCH 18, 2023

The eagerly anticipated results from a Phase 2 study in psoriasis show why the pharma paid $4 billion to buy the drug from startup Nimbus Therapeutics last year

Drugs 246

Drugs 246

Drug Patent Watch

MARCH 18, 2023

Annual Drug Patent Expirations for INBRIJA Inbrija is a drug marketed by Acorda and is included in one NDA. It is available from one supplier. There are ten patents protecting… The post New patent expiration for Acorda drug INBRIJA appeared first on DrugPatentWatch - Make Better Decisions.

Marketing 52

Marketing Drugs 52

Cloudbyz

MARCH 18, 2023

Contract Research Organizations (CROs) play a crucial role in helping biotech companies conduct clinical trials and bring drugs to market.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Compliance 52

Drug Patent Watch

MARCH 18, 2023

Annual Drug Patent Expirations for OTEZLA Otezla is a drug marketed by Amgen Inc and is included in one NDA. It is available from one supplier. There are eleven patents… The post New patent expiration for Amgen Inc drug OTEZLA appeared first on DrugPatentWatch - Make Better Decisions.

Marketing 52

Marketing Drugs 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.

Drugs

Drug Patent Watch

MARCH 18, 2023

Five years of exclusivity is provided for drugs which do not contain active molecules that have appeared in previously-approved drugs. This is one of the longest exclusivity terms provided by… The post Pharmaceutical companies with the most ‘New Chemical Entity’ drugs appeared first on DrugPatentWatch - Make Better Decisions. Infographic

Containment 40

Containment Drugs 40